A substantial amount of research has been undertaken over the past decade to test these ideas. As a result, understanding the role of ECBs in controlling stress, fear, and anxiety has grown considerably in recent years, with some targets already having been advanced to preliminary clinical trials in patients. The broader literature on this topic has been covered in many excellent, comprehensive reviews [13] and will not be reiterated here. The focus of the current article is on one of the most rapidly moving developments in the field – the stress and anxiety-related role of a major modulatory component of the ECB system, known as fatty acid amide hydrolase (FAAH).
